Literature DB >> 6713687

The microheterogeneity of alpha 1-acid glycoprotein in inflammatory lung disease, cancer of the lung and normal health.

J E Hansen, V A Larsen, T C Bøg-Hansen.   

Abstract

The concentration of alpha 1-acid glycoprotein (AGP, orosomucoid) was measured in sera from 19 patients with primary squamous cell carcinoma of the lung, 16 patients with an inflammatory lung disease and 17 persons with normal health. All sera were further subjected to crossed immuno-affinoelectrophoresis with addition of Con A in the first dimension and sugar in the second dimension. The distribution of AGP into four microheterogeneity forms, which were the result of this analysis, was estimated by measuring the area under the precipitation curve. The microheterogeneity patterns of AGP in the three groups were significantly different from each other (p less than 0.001). The total concentration of AGP in the two groups of patients was significantly different from the concentration in the healthy group (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6713687     DOI: 10.1016/0009-8981(84)90352-8

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  18 in total

1.  Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein.

Authors:  M J Treuheit; C E Costello; H B Halsall
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

2.  Glycosylation of alpha1-acid glycoprotein in inflammatory disease: analysis by high-pH anion-exchange chromatography and concanavalin A crossed affinity immunoelectrophoresis.

Authors:  I Rydén; G Skude; A Lundblad; P Påhlsson
Journal:  Glycoconj J       Date:  1997-06       Impact factor: 2.916

3.  Changes of immunoreactivity in alpha 1-antitrypsin in patients with autoimmune diseases.

Authors:  L Saso; B Silvestrini; R Lahita; C Y Cheng
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

4.  Abnormal glycosylation of alpha 2-macroglobulin, a non-acute-phase protein in patients with autoimmune diseases.

Authors:  L Saso; B Silvestrini; A Guglielmotti; R Lahita; C Y Cheng
Journal:  Inflammation       Date:  1993-08       Impact factor: 4.092

5.  Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?

Authors:  J Braun; F Sörgel; W P Gluth; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Enhanced expression of alpha1-acid glycoprotein and fucosylation in hepatitis B patients provides an insight into pathogenesis.

Authors:  Gautam Mondal; Urmimala Chatterjee; Hasi R Das; Bishnu P Chatterjee
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

7.  Genetic studies of low-abundance human plasma proteins. V. Evidence for a second orosomucoid structural locus (ORM2) expressed in plasma.

Authors:  M H Escallon; R E Ferrell; M I Kamboh
Journal:  Am J Hum Genet       Date:  1987-09       Impact factor: 11.025

8.  A simple and rapid fluorometric determination method of alpha 1-acid glycoprotein in serum using quinaldine red.

Authors:  H Imamura; T Maruyama; H Okabe; H Shimada; M Otagiri
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

9.  Changes in serum glycoprotein glycosylation during experimental inflammation in mice are general, unrelated to protein type, and opposite changes in man and rat: studies on mouse serum alpha 1-acid glycoprotein, alpha 1-esterase, and alpha 1-protease inhibitor.

Authors:  P M Heegaard
Journal:  Inflammation       Date:  1992-12       Impact factor: 4.092

Review 10.  Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer.

Authors:  A Mackiewicz; K Mackiewicz
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.